RTW Biotech Opportunities

Edison Investment Research is terminating coverage on RTW Biotech Opportunities (RTW). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Equities

Equities by Sector

Sectors

Thematics

Latest

Inside the mind of investors: Oberon Investments

UK equities: Not wrong to call them, but Europe surprised

MediaWatch – What now?

Audiovisual

Latest

Take on Trusts – March 2025

Patria Private Equity Trust in 60 seconds

OSE Immunotherapeutics — Lusvertikimab and the future of IBD: KOL insights post-ECCO webinar

About Edison

About Edison

Careers

RTW Biotech Opportunities (LSE: RTW)

Latest Insights

RTW Biotech Opportunities – executive interview

RTW Biotech Opportunities – Significant acquisition of Arix Bioscience’s assets

RTW Biotech Opportunities — Use of Prometheus Biosciences’ sale proceeds

RTW Venture Fund — Finding value in the out-of-favour biotech sector

Sector

Research

RTW Venture Fund Limited — ‘One-stop shop’ for biotech lifecycle investment

RTW Venture Fund Limited — ‘One-stop shop’ for biotech lifecycle investment

US small-cap equities – Time to shine?

Emerging markets – Worthy of consideration

Dynam Capital at the 2024 Vietnam ESG Conference

UK stock market – Scope for further upside in UK large-cap stocks

Listed private equity – Performing a balancing act

European equities

Listed Private Equity

Vietnamese equities: Due a comeback?

Investment companies: Latin America is worthy of consideration

IPO apocalypse

ESG, moving beyond the box tick

The case for US capital markets

Value Investing: Living with the reality, waiting for the inevitable

Illuminator: August Update

Post Woodford- A spotlight on smaller company liquidity

How to buy and sell investment trusts

Types of investment trusts

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Investment Trusts Quarterly: Biotechnology & healthcare trusts

Investment Trusts Quarterly: Growth and income